sq-11725 has been researched along with Hemangioma, Capillary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Drolet, B; Kanigsberg, N; Lara-Corrales, I; Liy-Wong, C; Ma, J; Pope, E; Sibbald, C | 1 |
| Baumann, T; LeRoy, J; McGillis, E | 1 |
| Fruge, JH; Massengale, WT; Rouhana, HF | 1 |
1 review(s) available for sq-11725 and Hemangioma, Capillary
| Article | Year |
|---|---|
Beta blocker treatment for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemangioma, Capillary; Humans; Infant; Male; Nadolol; Propranolol; Skin Neoplasms; Timolol; Treatment Outcome | 2015 |
1 trial(s) available for sq-11725 and Hemangioma, Capillary
| Article | Year |
|---|---|
Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Double-Blind Method; Equivalence Trials as Topic; Female; Hemangioma, Capillary; Humans; Infant; Male; Nadolol; Neoplastic Syndromes, Hereditary; Ontario; Propranolol; Prospective Studies; Treatment Outcome | 2022 |
1 other study(ies) available for sq-11725 and Hemangioma, Capillary
| Article | Year |
|---|---|
Death Associated With Nadolol for Infantile Hemangioma: A Case for Improving Safety.
Topics: Adrenergic beta-Antagonists; Constipation; Facial Neoplasms; Fatal Outcome; Female; Hemangioma, Capillary; Humans; Infant; Nadolol | 2020 |